KNSA as reported
Kiniksa Pharmaceuticals International, plc reported $754M of revenue over the trailing twelve months, +57% on the year before. 10 reported series are charted on this page, each one as filed.
$754M
Revenue, trailing twelve months · to Q1 2026 · +57% against the twelve months before
- Net Income
- $73M
Net Income · −531% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $164M
Free Cash Flow · +276% year on year · trailing twelve months to Q1 2026
- Op Margin
- 12%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $754M | +57% | Q1 2026 |
| Net Income | $73M | −531% | Q1 2026 |
| EPS | $0.91 | −464% | Q1 2026 |
| Gross Margin | 89% | n/a | Q1 2026 |
| Op Margin | 12% | n/a | Q1 2026 |
| Net Margin | 9.8% | n/a | Q1 2026 |
| ROE | 7.5% | n/a | Q1 2026 |
| ROA | 5.6% | n/a | Q1 2026 |
| Free Cash Flow | $164M | +276% | Q1 2026 |
| P/E | 86.5 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Kiniksa Pharmaceuticals International, plc (KNSA) - Revenue & ProfitRevenue & ProfitKiniksa Pharmaceuticals International, plc (KNSA)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - Specialty & Generic
Ranks #18 of 28 by Smart Score